Serial tumor and control tissue biopsies taken before and after the administration of RGD-A-TNF provided an opportunity to correlate drug exposure with tumor and normal tissue trafficking of RGD-A-TNF. These experiments validated the tumor-specific targeting of the RGD-A-TNF in the setting of dogs with spontaneous cancers. The gene discussed is TNF; the disease is cancer.